Abstract: PD-1/PD-L1 blockade therapy is a representative immunotherapy that shows a major breakthrough in cancer therapy and dermatologic reactions are the most prevalent immune-related adverse events (irAEs). We reported 4 cases of different skin irAEs, including eczema, erythema multiforme, TEN, eosinophilic dermatitis. And the studies of dermatologic reactions induced by PD-1/PD-L1 blockade from Pubmed since 2015 were respectively analyzed, including sex, age, drug and lesion type, etc. In order to improve the attention of irAEs manifested as skin disease, to timely treat the patient with life-threatening adverse reactions, and to help improve the quality of life and prognosis of tumor patients.

Key words: cancer immune therapy, checkpoint inhibitors, irAEs manifested as skin disease